louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00944164: Primary Care Obesity Prevention and Treatment
Official title: Test the Feasibility of Primary Care Obesity Prevention and Treatment - Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Lead sponsor: University of Washington
Sponsor class: OTHER
Collaborators: name: Group Health
name: Fred Hutchinson Cancer Center
First posted: 2009-07-23
Enrollment: 176
Sex: ALL
Minimum age (years): 5
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The overall objective of this pilot is to demonstrate the feasibility of a low-cost intervention targeting obesity prevention among children in a primary care setting.

Specifically, the investigators aim to answer the following questions:

Can the investigators recruit and retain patients using the methods proposed, and how easy or difficult will this process be?

Can physicians deliver the proposed intervention messages in the time the investigators have proposed?

Can the phone counselor reach participants and accomplish the goals outlined for these calls?

Can the investigators obtain the data proposed and within the proposed time frame?


Eligibility criteria: Inclusion Criteria:

* child BMI ≥ 70th percentile for age and sex according to CDC Growth Tables
* child scheduled for an upcoming well child visit

Primary outcomes:
measure: Feasibility of recruiting and retaining families
timeFrame: Enrollment to 3-month followup
Secondary outcomes:
measure: Child weight (BMI)
timeFrame: Baseline and 3-months post
measure: Parental perceptions of child weight
timeFrame: Baseline and 3-months post intervention
measure: Satisfaction with intervention
timeFrame: 3-months post intervention
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: Health Partners Research Foundation
state: Minnesota
city: Seattle
country: United States
facility: University of Washington
state: Washington
Study officials:
affiliation: University of Washington
name: Rona L Levy, MSW, PhD, MPH
role: PRINCIPAL_INVESTIGATOR
affiliation: Health Partners Research Foundation
name: Nancy Sherwood, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04845464: Sleep Quality and Cognition in Young Adults
Official title: The Relationship Between Sleep Quality and Cognition in Young Adults
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy Adults
Keywords: Sleep Quality
Cognitive Status
healthy adult
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
First posted: 2021-04-15
Enrollment: 122
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy adults aged between 18 to 25

Brief summary: Sleep quality is impaired in young adults due to current conditions. Recent studies emphasize that this situation may also affect the cognitive status of individuals. The aim of this study was to investigate the relationship between sleep quality and cognitive status in young adults. A total of 122 young adults (61 female, 61 male) aged between 18 to 25 and studied at Istanbul Medipol University, Faculty of Health Sciences, were included in the study. Individuals were evaluated with "Pittsburgh Sleep Quality Index (PSQI)" for sleep quality; with "Montreal Cognitive Status Scale (MoCA)" for cognitive status, with "STROOP Test" for selective attention; with "Verbal Fluency Test" for sustained attention; with "WMS-R digit Span Test" for auditory attention


Eligibility criteria: Inclusion Criteria:

* Signing the Informed Voluntary Consent Form
* Being in the age range of 18-25

Exclusion Criteria:

* having a sleep disorder

Primary outcomes:
measure: Pittsburgh Sleep Quality Index
timeFrame: 8 March - 26 April 2019
measure: Montreal Cognitive Assessment Test
timeFrame: 8 March - 26 April 2019
Secondary outcomes:
measure: STROOP Test
timeFrame: 8 March - 26 April 2019
measure: Verbal Fluency Test
timeFrame: 8 March - 26 April 2019
measure: WMS-R digit Span Test
timeFrame: 8 March - 26 April 2019
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Medipol University
Study officials:
References:
Clinical trial NCT03359564: Microendoscopic Lumbar Discectomy: A Study of 100 Cases
Official title: Microendoscopic Lumbar Discectomy: A Prospective Study of 100 Cases
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lumbar Disc Herniation
Keywords: Lumbar Disc Herniation
Micro Endoscopic Discectomy
Lead sponsor: Peking University People's Hospital
Sponsor class: OTHER
First posted: 2017-12-02
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who underwent surgery for herniated disc using the tubular retractor

Brief summary: Evaluate the outcome of micro endoscopic discectomy (MED) by tubular retractors on safety and efficacy of the technique.

Detailed description: Evaluate the outcome of micro endoscopic discectomy (MED) by tubular retractors on safety and efficacy of the technique.Patients who underwent surgery for herniated disc using the tubular retractors. The results were evaluated by using VAS (Visual Analog Scale 0-5) for back and leg pain and ODI (Oswestry Disability Index). Patients were followed up at intervals of 1 week, 6 weeks, 3 months, 6 months, 12 months and 2 years after surgery.

Eligibility criteria: Inclusion Criteria:

* Patients with at least 6 weeks of conservative treatment with positive nerve root tension signs, radicular pain
* Patients are diagnosed with lumbar disc herniation by MRI
* Patients who underwent surgery for herniated disc using the tubular retractor

Exclusion Criteria:

* Patients with large central disc herniation, chronic discogenic pain, discitis, multi-level disease, presence of instability or history of lumbar surgery

Primary outcomes:
measure: Oswestry Disability Index
timeFrame: 2 years after operation
Secondary outcomes:
measure: Oswestry Disability Index
timeFrame: preoperative evaluation and 1 week, 6 weeks, 3 months, 6 months, 12 months after operation
measure: Visual Analog Scale
timeFrame: preoperative evaluation and 1 week, 6 weeks, 3 months, 6 months, 12 months and 2 years postoperative follow-up
Other outcomes:
Locations:
Study officials:
affiliation: department of spinal surgery,PekingUPH
name: GUO chen, bachelor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00383864: Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation.
Official title: Randomized Study on the Efficacy and Safety of Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hepatitis C
Keywords: liver fibrosis
portal pressure
antiviral therapy
Lead sponsor: Hospital Clinic of Barcelona
Sponsor class: OTHER
Collaborators: name: Schering-Plough
First posted: 2006-10-04
Enrollment: 55
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to evaluate the efficacy (and safety) of antiviral therapy in patients with chronic hepatitis C after liver transplantation. The only approved drugs for treatment of hepatitis C are pegylated interferon and ribavirin.

Detailed description: Hepatitis C recurrence after liver transplantation remains the main cause of graft loss after liver transplantation. Several strategies can be used to prevent or treat hepatitis C in the setting of liver transplantation. There are no controlled studies evaluating the efficacy and safety of antiviral treatment (using pegylated interferon and ribavirin) in liver transplant recipients. The main endpoint of this study was: 1) histological outcomes (effect of antiviral treatment on disease progression, i.e. liver fibrosis). The secondary endpoint were 1) Sustained virological response (persistent HCV-RNA clearance) and 2) Safety of pegylated interferon and ribavirin

Eligibility criteria: Inclusion Criteria:

* Chronic hepatitis C defined by liver biopsy and presence of HCV-RNA
* More than 6 months from liver transplantation
* Written inform consent

Exclusion Criteria:

* Severe hepatitis C recurrence (F3-F4 fibrosis stage, cholestatic hepatitis)
* Double liver-kidney transplantation
* Leucopenia (2000) or thrombocytopenia (40.000)
* Anemia (Hemoglobin lower than 10 g/dL)
* Renal failure (creatinine \> 2 mg/dL)
* Autoimmune disease
* All contraindications for interferon and ribavirin therapy

Primary outcomes:
measure: Histological improvement (decrease in at least one fibrosis stage in follow-up liver biop
Secondary outcomes:
measure: Sustained virological response (persistent HCV-RNA negativation)
measure: Safety of antiviral therapy
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Liver Unit, Hospital Clinic
Study officials:
affiliation: Liver Unit, Hospital Clinic, Barcelona
name: Xavier Forns, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Carrion JA, Navasa M, Garcia-Retortillo M, Garcia-Pagan JC, Crespo G, Bruguera M, Bosch J, Forns X. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007 May;132(5):1746-56. doi: 10.1053/j.gastro.2007.03.041. Epub 2007 Mar 24.
Clinical trial NCT00430664: A Comparative Study of the Safety and Efficacy of Face Talc Slurry and Iodopovidone for Pleurodesis
Official title: A Comparative Study of the Safety and Efficacy of Face Talc Slurry and Iodopovidone for Pleurodesis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Malignant Pleural Effusions
Recurrent Pleural Effusions
Primary Spontaneous Pneumothorax
Secondary Spontaneous Pneumothorax
Keywords: pleurodesis
talc
iodopovidone
Lead sponsor: PIMERIndia
Sponsor class: UNKNOWN
First posted: 2007-02-02
Enrollment: 100
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Pleurodesis is a technique used to fuse the two layers of the lining over the lung. This is done to get rid of collections of fluid or air in this space. A common reason would be cancer of the underlying lung or elsewhere causing fluid to collect in the pleural space. In this situation it is a palliative procedure to free the patient from symptoms like breathlessness.

Detailed description: Pleurodesis is a technique used to fuse the two layers of the pleura. This is done to prevent reaccumulation of collections of fluid or air in this space. Common indications are malignant pleural effusions, recurrent pneumothorax and even benign effusions which are otherwise difficult to eradicate.

Eligibility criteria: Inclusion Criteria:

* Age over 12 years
* Symptomatic recurrent pleural effusion
* Pneumothorax needing pleurodesis

Exclusion Criteria:

* Life expectancy \<1 month
* Unwilling to give consent
* Empyema
* ICTD drain output \>150 ml/d
* Presence of an airleak

Primary outcomes:
measure: Success
measure: Failure
Secondary outcomes:
measure: Death
measure: Pain by VAS
measure: Time to Pleurodesis
measure: Others
Other outcomes:
Locations:
city: Chandigarh
country: India
facility: PGIMER
Study officials:
affiliation: Additional Professor, Dept of Pulmonary Medicine, PGIMER, Chandigarh, India
name: Dheeraj Gupta, MD, DM, FCCP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01392664: TVTO Versus TVTFFM for Urinary Stress Incontinence
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Urinary Stress Incontinence Treated by TVT
Lead sponsor: Western Galilee Hospital-Nahariya
Sponsor class: OTHER_GOV
First posted: 2011-07-12
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women with Urinary Stress Incontinence treated by TVT

Brief summary: Women who had urinary stress incontinence and underwent one of two procedures: the classic TVTO or the Folke-Flam method of surgical operation, will be evaluated and compared.

Detailed description: We will enroll women that underwent one of the two surgeries: TVTO or the modification where the needle passes somewhat to the side to prevent the post operative pain, for urinary stress incontinence. Data will be collected from the charts. Telephone interviews will be carried out. Physical examination will also be incorporated.

Eligibility criteria: Inclusion Criteria:

* Women with Urinary Stress Incontinence treated by TVT

Exclusion Criteria:

* Women without with Urinary Stress Incontinence or not treated by TVT

Primary outcomes:
measure: Resolution of urinary stress incontinence
timeFrame: One year after surgery
Secondary outcomes:
measure: Side effect of surgery
timeFrame: six-12 months
Other outcomes:
Locations:
city: Nahariya
country: Israel
facility: Department of Obstetrics and Gynecology, Western Galilee Hospital
city: Tel Aviv
country: Israel
facility: Clinics of Dr Neuman
Study officials:
References:
Clinical trial NCT03835364: Aptus at Home: Co-design of a Home-based Monitoring System for Anaemia
Official title: Aptus at Home: Co-design of a Home-based Monitoring System for Anaemia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anemia
Iron Deficiency Anemia
Lead sponsor: Entia Ltd
Sponsor class: INDUSTRY
First posted: 2019-02-08
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Anyone over 18 years of age with a prior diagnosis of anaemia, who have the capability to sign consent for the themselves and commit to the requirements of the study.

Brief summary: Co-design of a home-based anaemia monitoring system with participants who have previous diagnosis of anaemia.

Detailed description: The device/ monitoring system being developed is called Aptus home. Aptus home measures the haemoglobin and haematocrit levels in blood from a single drop of blood. By measuring these blood parameters, participants are able to monitor anaemia in participants' homes.

The use of the device will take place in the participant's home to simulate what the investigators believe will be the ideal location for people who would prefer to self-manage their condition.

This study is a unique opportunity to gain feedback on the future design and development of a home-based monitoring system through user evaluation. As this is an adaptive/ iterative study design, this will give the Sponsor the opportunity to make changes to the user interface and user platform based on the feedback received from the end user.

Eligibility criteria: Inclusion Criteria:

* Prior diagnosis of anaemia
* Commitment to perform finger pricking to use the device every two weeks and complete 2 monthly questionnaires
* Participant's willingness to participate in 1 to 1 interviews and, or focus groups
* Understands and has a good level of spoken and written English

Exclusion Criteria:

* No prior diagnosis of anaemia
* Not committed to perform two weekly finger pricks to use device and complete 2 monthly questionnaires
* Unwilling to attend interviews and focus groups
* Doesn't have a good level of written and spoken English

Primary outcomes:
measure: Qualitative capture of user feedback- Questionnaires
timeFrame: 14 months
measure: Qualitative capture of user feedback- focus groups
timeFrame: 14 months
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Entia Ltd, Room G11, Screenworks, Highbury Grove, Highbury and Islington
Study officials:
References:
Clinical trial NCT05889364: AI-based System for Lung Tuberculosis Screening: Diagnostic Accuracy Evaluation
Official title: AI-based System for Lung Tuberculosis Screening: Diagnostic Accuracy Evaluation
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Tuberculosis, Pulmonary
Keywords: AI
deep learning
tuberculosis
radiology
x-ray
e-health
screening
chest
artificial intelligence
Lead sponsor: Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
Sponsor class: OTHER
First posted: 2023-06-05
Enrollment: 308
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 308 chest x-ray images selected from the database of Unified Radiological Information Service (URIS) of Moscow

Brief summary: Testing of AI solutions to assess diagnostic accuracy for tuberculosis detection.

Detailed description: Tuberculosis remains a key problem of modern medicine. New approaches for burden overcoming should be proposed. New screening strategies may include artificial intelligence (AI). An AI-based system for chest x-ray analysis and triage ("normal/tuberculosis suspected") have been developed and trained. A special data-set was prepared. There are 238 normal x-rays and 70 x-rays with lung tuberculosis in data-set. The data-set was randomly divided into 2 samples:

* sample N1 (n=140) with ratio "normal: tuberculosis" 50:50,
* sample N1 (n=150) with ratio "normal: tuberculosis" 95:5. Both samples will be analysed by AI-based system. Results will be quantified using diagnostic accuracy metrics: sensitivity and specificity, positive and negative predictor values, likelihood ratio, and area under the ROC (receiver operating characteristic) curve.

Eligibility criteria: Inclusion Criteria:

* no pathology in a lung on chest x-ray
* signs of lung tuberculosis on chest x-ray

Exclusion Criteria:

* any pathology in the lungs (except tuberculosis)

Primary outcomes:
measure: Diagnostic accuracy metric 1
timeFrame: Day 1 upon receipt of data
measure: Diagnostic accuracy metric 2
timeFrame: Day 2 upon receipt of data
measure: Diagnostic accuracy metric 3
timeFrame: Day 3 upon receipt of data
measure: Diagnostic accuracy metric 4
timeFrame: Day 4 upon receipt of data
measure: Diagnostic accuracy metric 5
timeFrame: Day 5 upon receipt of data
measure: Diagnostic accuracy metric 6
timeFrame: Day 6 upon receipt of data
Secondary outcomes:
Other outcomes:
Locations:
city: Moscow
country: Russian Federation
facility: Research and Practical Center of Medical Radiology, Department of Health Care of Moscow
Study officials:
affiliation: Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
name: Anton Vladzymyrskyy
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01616264: Reproducibility of Computed Tomography
Official title: Evaluation of the Reproducibility of Computed Tomography for the Measurement of Tuberculosis Pleural Effusion
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tuberculosis
Pleural Effusion
Keywords: Tuberculosis
Pleural Effusion
Computed Tomography
Lead sponsor: Universidade Federal do Rio de Janeiro
Sponsor class: OTHER
First posted: 2012-06-11
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients age 18 years or older with a confirmed diagnosis of pleural TB effusion

Brief summary: Thus, the aim of this study was to evaluate the reproducibility of the Computed Tomograph scan three-dimensional reconstruction method for the measurement of the TB pleural effusion volume in clinically stable patients.

Detailed description: Speed, accuracy, and precision in the quantification of pleural effusion are of critical importance as it determines whether or not thoracocentesis should be carried out and which technique should be employed for such a procedure. This study evaluates the precision of thoracic computed tomography with three-dimensional (3D) rebuilding in determining the volume of tuberculosis pleural effusion.Twenty patients with pleural effusion were screened and invited to take part in the study. Each patient underwent two computed tomography scans, before and after one month of treatment for tuberculosis, a total of 40 exams. These were evaluated by two expert radiologists. In conclusion, the quantification of the pleural effusion volume by using thoracic CT with volumetric three-dimensional reconstruction is a highly reproducible method.

Eligibility criteria: Inclusion Criteria:

* Patients age 18 years with a confirmed diagnosis of pleural TB effusion .
* Signed out an informed consent term

Exclusion Criteria:

* Patients with human immunodeficiency virus (HIV).

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Universidade Federal do Rio de Janeiro
name: Juliana F Oliveira, Phd
role: PRINCIPAL_INVESTIGATOR
References: